| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 8 | 2025 | 49 | 2.350 |
Why?
|
| Adrenal Gland Neoplasms | 4 | 2023 | 19 | 1.850 |
Why?
|
| Breast Neoplasms | 11 | 2025 | 1679 | 1.580 |
Why?
|
| Checklist | 2 | 2021 | 16 | 1.360 |
Why?
|
| Thyroidectomy | 3 | 2025 | 10 | 1.200 |
Why?
|
| Research Design | 3 | 2021 | 370 | 1.180 |
Why?
|
| Neoadjuvant Therapy | 3 | 2025 | 23 | 1.160 |
Why?
|
| Hypoparathyroidism | 1 | 2025 | 2 | 0.930 |
Why?
|
| Adenoma | 2 | 2023 | 94 | 0.900 |
Why?
|
| Postoperative Complications | 2 | 2025 | 253 | 0.880 |
Why?
|
| Humans | 64 | 2025 | 42113 | 0.830 |
Why?
|
| Emergency Service, Hospital | 2 | 2025 | 268 | 0.810 |
Why?
|
| Adrenocortical Adenoma | 1 | 2022 | 1 | 0.780 |
Why?
|
| Animals, Domestic | 2 | 2021 | 11 | 0.720 |
Why?
|
| Lactase | 1 | 2021 | 1 | 0.700 |
Why?
|
| Fluoroimmunoassay | 1 | 2021 | 2 | 0.690 |
Why?
|
| Statistics as Topic | 1 | 2021 | 123 | 0.660 |
Why?
|
| Hydrocortisone | 1 | 2021 | 89 | 0.650 |
Why?
|
| Lymphotoxin-alpha | 1 | 2019 | 4 | 0.630 |
Why?
|
| Major Histocompatibility Complex | 1 | 2019 | 27 | 0.630 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 170 | 0.620 |
Why?
|
| Macrophages | 3 | 2013 | 515 | 0.620 |
Why?
|
| Selection, Genetic | 3 | 2018 | 75 | 0.590 |
Why?
|
| Thyroid Nodule | 1 | 2018 | 4 | 0.590 |
Why?
|
| Evolution, Molecular | 6 | 2021 | 299 | 0.580 |
Why?
|
| Polymorphism, Genetic | 2 | 2018 | 200 | 0.550 |
Why?
|
| Registries | 3 | 2025 | 430 | 0.550 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2017 | 3 | 0.540 |
Why?
|
| Cytodiagnosis | 1 | 2017 | 10 | 0.540 |
Why?
|
| Female | 33 | 2025 | 23980 | 0.540 |
Why?
|
| Carcinoma, Papillary | 1 | 2017 | 15 | 0.540 |
Why?
|
| Demography | 2 | 2021 | 195 | 0.530 |
Why?
|
| Retrospective Studies | 7 | 2025 | 2466 | 0.520 |
Why?
|
| Interferon-gamma | 1 | 2018 | 268 | 0.510 |
Why?
|
| Cell Nucleus | 1 | 2018 | 383 | 0.500 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2013 | 49 | 0.500 |
Why?
|
| Middle Aged | 19 | 2025 | 11790 | 0.490 |
Why?
|
| Prognosis | 10 | 2024 | 847 | 0.480 |
Why?
|
| Biomedical Research | 1 | 2021 | 467 | 0.470 |
Why?
|
| Neoplasm Staging | 5 | 2025 | 366 | 0.470 |
Why?
|
| Africa | 3 | 2021 | 81 | 0.470 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2023 | 244 | 0.420 |
Why?
|
| Renal Replacement Therapy | 1 | 2012 | 10 | 0.380 |
Why?
|
| Insulin Infusion Systems | 3 | 2018 | 8 | 0.380 |
Why?
|
| Medical Record Linkage | 1 | 2012 | 16 | 0.380 |
Why?
|
| Mortality | 2 | 2023 | 174 | 0.380 |
Why?
|
| Adult | 15 | 2025 | 13437 | 0.360 |
Why?
|
| Immunotherapy | 2 | 2025 | 137 | 0.360 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2018 | 85 | 0.360 |
Why?
|
| Antimalarials | 3 | 2024 | 63 | 0.350 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2024 | 575 | 0.350 |
Why?
|
| Plasmodium falciparum | 3 | 2024 | 146 | 0.340 |
Why?
|
| Predictive Value of Tests | 6 | 2024 | 437 | 0.320 |
Why?
|
| Kidney Failure, Chronic | 1 | 2012 | 239 | 0.320 |
Why?
|
| Diagnosis, Differential | 2 | 2022 | 236 | 0.310 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2019 | 858 | 0.310 |
Why?
|
| Enzyme Inhibitors | 2 | 2024 | 457 | 0.300 |
Why?
|
| Genetic Variation | 5 | 2018 | 429 | 0.300 |
Why?
|
| Aged | 11 | 2025 | 7958 | 0.290 |
Why?
|
| Hospitalization | 1 | 2012 | 477 | 0.290 |
Why?
|
| Male | 18 | 2025 | 22745 | 0.290 |
Why?
|
| Gene Frequency | 2 | 2019 | 203 | 0.280 |
Why?
|
| Adenocarcinoma | 2 | 2022 | 287 | 0.250 |
Why?
|
| MicroRNAs | 2 | 2023 | 501 | 0.250 |
Why?
|
| Brain Neoplasms | 2 | 2020 | 129 | 0.250 |
Why?
|
| Cardiovascular Diseases | 2 | 2024 | 728 | 0.250 |
Why?
|
| Columbidae | 2 | 2018 | 49 | 0.240 |
Why?
|
| Young Adult | 7 | 2025 | 4928 | 0.240 |
Why?
|
| Medical Oncology | 1 | 2025 | 46 | 0.230 |
Why?
|
| Genetics, Population | 2 | 2019 | 118 | 0.230 |
Why?
|
| Schistosomiasis | 1 | 2024 | 18 | 0.220 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2024 | 2 | 0.220 |
Why?
|
| Incidence | 2 | 2025 | 1052 | 0.220 |
Why?
|
| World Health Organization | 1 | 2024 | 36 | 0.220 |
Why?
|
| Antineoplastic Agents | 2 | 2024 | 979 | 0.210 |
Why?
|
| Lipids | 2 | 2023 | 256 | 0.210 |
Why?
|
| Drug Industry | 1 | 2024 | 18 | 0.210 |
Why?
|
| Antitubercular Agents | 1 | 2024 | 33 | 0.210 |
Why?
|
| Structure-Activity Relationship | 5 | 2024 | 491 | 0.210 |
Why?
|
| Emergencies | 1 | 2023 | 32 | 0.210 |
Why?
|
| Databases, Factual | 1 | 2025 | 335 | 0.200 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2023 | 2 | 0.200 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2023 | 2 | 0.200 |
Why?
|
| Pheochromocytoma | 1 | 2023 | 12 | 0.200 |
Why?
|
| Treatment Outcome | 3 | 2024 | 1582 | 0.200 |
Why?
|
| Cysts | 1 | 2023 | 10 | 0.200 |
Why?
|
| California | 1 | 2025 | 531 | 0.200 |
Why?
|
| Tuberculosis | 1 | 2024 | 76 | 0.200 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 1058 | 0.200 |
Why?
|
| Radiology | 1 | 2022 | 12 | 0.190 |
Why?
|
| Acute Coronary Syndrome | 1 | 2023 | 42 | 0.190 |
Why?
|
| Endocrine System Diseases | 1 | 2022 | 16 | 0.190 |
Why?
|
| Iodine | 1 | 2022 | 11 | 0.190 |
Why?
|
| Hemorrhage | 1 | 2022 | 55 | 0.190 |
Why?
|
| Animals | 11 | 2024 | 16694 | 0.190 |
Why?
|
| Killer Cells, Natural | 2 | 2021 | 99 | 0.190 |
Why?
|
| Gastrointestinal Diseases | 1 | 2022 | 51 | 0.190 |
Why?
|
| Clostridium Infections | 1 | 2022 | 8 | 0.180 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2022 | 8 | 0.180 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 2 | 2024 | 8 | 0.180 |
Why?
|
| Adolescent | 6 | 2025 | 5949 | 0.180 |
Why?
|
| Air Pollution | 1 | 2023 | 87 | 0.180 |
Why?
|
| Myocarditis | 1 | 2021 | 24 | 0.180 |
Why?
|
| Drug Delivery Systems | 1 | 2024 | 273 | 0.180 |
Why?
|
| Bacterial Toxins | 1 | 2022 | 50 | 0.180 |
Why?
|
| Cross Infection | 1 | 2022 | 47 | 0.180 |
Why?
|
| Air Pollutants | 1 | 2023 | 127 | 0.170 |
Why?
|
| Abdomen | 1 | 2021 | 13 | 0.170 |
Why?
|
| Databases, Genetic | 2 | 2021 | 103 | 0.170 |
Why?
|
| Genomics | 3 | 2023 | 289 | 0.170 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2023 | 290 | 0.170 |
Why?
|
| Sports Medicine | 1 | 2021 | 6 | 0.170 |
Why?
|
| Peer Review, Research | 1 | 2021 | 15 | 0.170 |
Why?
|
| Sensitivity and Specificity | 1 | 2022 | 602 | 0.170 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 25 | 0.170 |
Why?
|
| Tissue Array Analysis | 1 | 2021 | 79 | 0.170 |
Why?
|
| Malaria, Falciparum | 2 | 2024 | 91 | 0.170 |
Why?
|
| Quantitative Trait Loci | 1 | 2021 | 88 | 0.170 |
Why?
|
| Africa South of the Sahara | 1 | 2020 | 51 | 0.170 |
Why?
|
| Isoxazoles | 1 | 2020 | 14 | 0.170 |
Why?
|
| Risk Factors | 3 | 2025 | 3933 | 0.170 |
Why?
|
| Heterocyclic Compounds | 1 | 2020 | 23 | 0.160 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 242 | 0.160 |
Why?
|
| Sudden Infant Death | 1 | 2020 | 7 | 0.160 |
Why?
|
| Germ-Line Mutation | 1 | 2021 | 74 | 0.160 |
Why?
|
| Cell Movement | 1 | 2024 | 640 | 0.160 |
Why?
|
| Siblings | 1 | 2020 | 22 | 0.160 |
Why?
|
| Fluorescence | 1 | 2020 | 113 | 0.160 |
Why?
|
| Human Genome Project | 1 | 2019 | 7 | 0.160 |
Why?
|
| Malaria | 2 | 2024 | 90 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2019 | 20 | 0.160 |
Why?
|
| Amides | 1 | 2020 | 72 | 0.160 |
Why?
|
| Hominidae | 1 | 2019 | 12 | 0.160 |
Why?
|
| Algorithms | 3 | 2017 | 508 | 0.160 |
Why?
|
| Fluorescent Dyes | 1 | 2021 | 182 | 0.160 |
Why?
|
| Linkage Disequilibrium | 1 | 2019 | 85 | 0.160 |
Why?
|
| Breast | 1 | 2021 | 139 | 0.160 |
Why?
|
| Cattle | 1 | 2021 | 505 | 0.160 |
Why?
|
| Genome | 2 | 2018 | 149 | 0.150 |
Why?
|
| Haplotypes | 1 | 2019 | 197 | 0.150 |
Why?
|
| Oxyphil Cells | 1 | 2018 | 1 | 0.150 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2018 | 12 | 0.150 |
Why?
|
| Thyroid Gland | 1 | 2018 | 23 | 0.140 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 378 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2021 | 933 | 0.140 |
Why?
|
| Quantitative Trait, Heritable | 2 | 2021 | 27 | 0.140 |
Why?
|
| Ultrasonography | 1 | 2018 | 132 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 508 | 0.140 |
Why?
|
| Knowledge Bases | 1 | 2018 | 8 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 309 | 0.140 |
Why?
|
| Insulin | 2 | 2017 | 255 | 0.140 |
Why?
|
| Preoperative Care | 1 | 2017 | 31 | 0.130 |
Why?
|
| Gene Expression Regulation, Plant | 1 | 2018 | 65 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 357 | 0.130 |
Why?
|
| Molecular Structure | 3 | 2024 | 560 | 0.130 |
Why?
|
| Ventricular Function, Left | 2 | 2015 | 111 | 0.130 |
Why?
|
| Stroke Volume | 2 | 2015 | 122 | 0.130 |
Why?
|
| Plants | 1 | 2018 | 114 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 284 | 0.120 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 50 | 0.120 |
Why?
|
| Social Class | 2 | 2021 | 286 | 0.120 |
Why?
|
| Pyrimidines | 1 | 2016 | 130 | 0.120 |
Why?
|
| Plasmodium | 1 | 2015 | 16 | 0.120 |
Why?
|
| Cell Proliferation | 3 | 2024 | 1420 | 0.110 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2015 | 3 | 0.110 |
Why?
|
| Sample Size | 1 | 2015 | 28 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 3 | 2024 | 175 | 0.110 |
Why?
|
| Databases, Protein | 2 | 2006 | 54 | 0.110 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2015 | 30 | 0.110 |
Why?
|
| Protozoan Proteins | 1 | 2016 | 196 | 0.110 |
Why?
|
| Quinolines | 1 | 2015 | 76 | 0.110 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2014 | 4 | 0.110 |
Why?
|
| Immune Evasion | 1 | 2014 | 17 | 0.110 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 1051 | 0.110 |
Why?
|
| Protein Biosynthesis | 1 | 2015 | 136 | 0.110 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2014 | 64 | 0.110 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 96 | 0.100 |
Why?
|
| Heart Ventricles | 1 | 2015 | 123 | 0.100 |
Why?
|
| Disease-Free Survival | 3 | 2023 | 116 | 0.100 |
Why?
|
| Ventricular Function, Right | 1 | 2013 | 33 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2024 | 1111 | 0.100 |
Why?
|
| Glioblastoma | 1 | 2014 | 69 | 0.100 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2013 | 35 | 0.100 |
Why?
|
| Creatinine | 1 | 2013 | 102 | 0.100 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2013 | 43 | 0.100 |
Why?
|
| Albuminuria | 1 | 2013 | 78 | 0.100 |
Why?
|
| Head | 1 | 2013 | 28 | 0.100 |
Why?
|
| Gene Expression Profiling | 3 | 2023 | 683 | 0.100 |
Why?
|
| Hypertension, Pulmonary | 1 | 2013 | 78 | 0.100 |
Why?
|
| Hemodialysis Units, Hospital | 1 | 2012 | 4 | 0.100 |
Why?
|
| Software | 3 | 2018 | 234 | 0.100 |
Why?
|
| Cell Differentiation | 1 | 2016 | 633 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 233 | 0.090 |
Why?
|
| International Classification of Diseases | 1 | 2012 | 28 | 0.090 |
Why?
|
| Patient Admission | 1 | 2012 | 50 | 0.090 |
Why?
|
| Medication Adherence | 2 | 2024 | 177 | 0.090 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2024 | 147 | 0.090 |
Why?
|
| Proteins | 2 | 2006 | 383 | 0.090 |
Why?
|
| Data Collection | 1 | 2012 | 210 | 0.090 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2011 | 31 | 0.090 |
Why?
|
| Hospital Mortality | 1 | 2012 | 205 | 0.080 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2013 | 188 | 0.080 |
Why?
|
| Rosaceae | 1 | 2010 | 1 | 0.080 |
Why?
|
| Prunus | 1 | 2010 | 2 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 150 | 0.080 |
Why?
|
| Recurrence | 1 | 2010 | 149 | 0.080 |
Why?
|
| Neoplasms | 1 | 2021 | 1341 | 0.080 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 1066 | 0.080 |
Why?
|
| Comorbidity | 1 | 2012 | 723 | 0.080 |
Why?
|
| Drug Discovery | 2 | 2024 | 106 | 0.080 |
Why?
|
| Mice | 5 | 2024 | 6490 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2010 | 362 | 0.080 |
Why?
|
| Obesity | 1 | 2017 | 1129 | 0.080 |
Why?
|
| RNA, Messenger | 3 | 2021 | 1265 | 0.080 |
Why?
|
| Cell Line, Tumor | 3 | 2024 | 2598 | 0.070 |
Why?
|
| Computational Biology | 3 | 2021 | 324 | 0.070 |
Why?
|
| Age Factors | 3 | 2016 | 1135 | 0.070 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2018 | 76 | 0.070 |
Why?
|
| Genome-Wide Association Study | 2 | 2021 | 421 | 0.060 |
Why?
|
| Ecosystem | 2 | 2023 | 171 | 0.060 |
Why?
|
| Cluster Analysis | 2 | 2017 | 206 | 0.060 |
Why?
|
| Sequence Analysis, Protein | 1 | 2006 | 51 | 0.060 |
Why?
|
| Disease Progression | 2 | 2022 | 660 | 0.060 |
Why?
|
| Models, Genetic | 2 | 2017 | 181 | 0.060 |
Why?
|
| Schistosomicides | 1 | 2024 | 1 | 0.060 |
Why?
|
| Schistosoma | 1 | 2024 | 3 | 0.060 |
Why?
|
| Receptors, Progesterone | 1 | 2025 | 90 | 0.060 |
Why?
|
| United States | 3 | 2023 | 5068 | 0.060 |
Why?
|
| Quality of Life | 2 | 2022 | 598 | 0.060 |
Why?
|
| Schistosoma mansoni | 1 | 2024 | 21 | 0.050 |
Why?
|
| Mice, SCID | 1 | 2024 | 158 | 0.050 |
Why?
|
| Anthelmintics | 1 | 2024 | 21 | 0.050 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2024 | 6 | 0.050 |
Why?
|
| Rifampin | 1 | 2024 | 8 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2024 | 35 | 0.050 |
Why?
|
| Internet | 2 | 2022 | 234 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2024 | 93 | 0.050 |
Why?
|
| Infant | 2 | 2020 | 1142 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2025 | 177 | 0.050 |
Why?
|
| Ethical Review | 1 | 2023 | 3 | 0.050 |
Why?
|
| Patient Preference | 1 | 2024 | 55 | 0.050 |
Why?
|
| Troponin T | 1 | 2023 | 10 | 0.050 |
Why?
|
| Troponin | 1 | 2023 | 17 | 0.050 |
Why?
|
| Triazoles | 1 | 2024 | 100 | 0.050 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2023 | 68 | 0.050 |
Why?
|
| User-Computer Interface | 2 | 2018 | 74 | 0.050 |
Why?
|
| Consensus | 1 | 2022 | 53 | 0.050 |
Why?
|
| Amino Acid Substitution | 2 | 2017 | 135 | 0.050 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2022 | 5 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2022 | 39 | 0.050 |
Why?
|
| Drug Design | 1 | 2024 | 183 | 0.050 |
Why?
|
| Vaccines, Conjugate | 1 | 2022 | 9 | 0.050 |
Why?
|
| Quality of Health Care | 1 | 2023 | 158 | 0.050 |
Why?
|
| Seasons | 1 | 2023 | 133 | 0.050 |
Why?
|
| Receptor, erbB-2 | 1 | 2023 | 149 | 0.050 |
Why?
|
| Ribotyping | 1 | 2022 | 3 | 0.050 |
Why?
|
| Cancer Vaccines | 1 | 2022 | 26 | 0.050 |
Why?
|
| Western Australia | 1 | 2022 | 7 | 0.050 |
Why?
|
| Hot Temperature | 1 | 2023 | 141 | 0.050 |
Why?
|
| Immunity, Humoral | 1 | 2022 | 26 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2022 | 87 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 209 | 0.040 |
Why?
|
| Temperature | 1 | 2023 | 314 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2022 | 117 | 0.040 |
Why?
|
| Retinoblastoma-Like Protein p107 | 1 | 2021 | 1 | 0.040 |
Why?
|
| Japan | 1 | 2022 | 347 | 0.040 |
Why?
|
| Genes, BRCA1 | 1 | 2021 | 20 | 0.040 |
Why?
|
| ROC Curve | 1 | 2021 | 157 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2013 | 512 | 0.040 |
Why?
|
| Wnt Proteins | 1 | 2021 | 23 | 0.040 |
Why?
|
| Interferons | 1 | 2021 | 37 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 115 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 253 | 0.040 |
Why?
|
| Infanticide | 1 | 2020 | 1 | 0.040 |
Why?
|
| Accidents | 1 | 2020 | 6 | 0.040 |
Why?
|
| Asphyxia | 1 | 2020 | 7 | 0.040 |
Why?
|
| beta Catenin | 1 | 2021 | 75 | 0.040 |
Why?
|
| RNA Interference | 1 | 2021 | 246 | 0.040 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2021 | 300 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 150 | 0.040 |
Why?
|
| Puerto Rico | 1 | 2023 | 1376 | 0.040 |
Why?
|
| Child Abuse | 1 | 2020 | 90 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2023 | 1570 | 0.040 |
Why?
|
| Parenting | 1 | 2020 | 135 | 0.040 |
Why?
|
| Synteny | 1 | 2018 | 18 | 0.040 |
Why?
|
| Scotland | 1 | 2018 | 3 | 0.040 |
Why?
|
| England | 1 | 2018 | 11 | 0.040 |
Why?
|
| Gene Library | 1 | 2018 | 60 | 0.040 |
Why?
|
| DNA Transposable Elements | 1 | 2018 | 50 | 0.030 |
Why?
|
| Genetic Research | 1 | 2018 | 11 | 0.030 |
Why?
|
| Genome, Plant | 1 | 2018 | 29 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2018 | 198 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2018 | 146 | 0.030 |
Why?
|
| Open Reading Frames | 1 | 2017 | 81 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2018 | 71 | 0.030 |
Why?
|
| Exons | 1 | 2017 | 91 | 0.030 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2017 | 2 | 0.030 |
Why?
|
| State Medicine | 1 | 2017 | 9 | 0.030 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2017 | 9 | 0.030 |
Why?
|
| Cell Survival | 1 | 2020 | 934 | 0.030 |
Why?
|
| Hypoglycemia | 1 | 2017 | 24 | 0.030 |
Why?
|
| Proteinuria | 1 | 2017 | 55 | 0.030 |
Why?
|
| Immune System | 1 | 2016 | 40 | 0.030 |
Why?
|
| New South Wales | 1 | 2016 | 2 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2013 | 1188 | 0.030 |
Why?
|
| Dogs | 1 | 2016 | 201 | 0.030 |
Why?
|
| Brazil | 1 | 2016 | 83 | 0.030 |
Why?
|
| North America | 1 | 2016 | 85 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2020 | 377 | 0.030 |
Why?
|
| Peptide Elongation Factor 2 | 1 | 2015 | 5 | 0.030 |
Why?
|
| Plasmodium vivax | 1 | 2015 | 8 | 0.030 |
Why?
|
| Nomograms | 1 | 2015 | 14 | 0.030 |
Why?
|
| Life Cycle Stages | 1 | 2015 | 30 | 0.030 |
Why?
|
| Genotype | 1 | 2018 | 792 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 114 | 0.030 |
Why?
|
| Body Weight | 1 | 2017 | 428 | 0.030 |
Why?
|
| Plasmodium berghei | 1 | 2015 | 35 | 0.030 |
Why?
|
| Markov Chains | 2 | 2006 | 42 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 274 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2017 | 386 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 2014 | 21 | 0.030 |
Why?
|
| Rats | 2 | 2016 | 3701 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 353 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2014 | 32 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2014 | 31 | 0.030 |
Why?
|
| Anxiety | 1 | 2022 | 847 | 0.030 |
Why?
|
| Body Surface Area | 1 | 2013 | 4 | 0.030 |
Why?
|
| Isoenzymes | 1 | 2014 | 169 | 0.030 |
Why?
|
| Diet, Protein-Restricted | 1 | 2013 | 7 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 727 | 0.030 |
Why?
|
| Glioma | 1 | 2014 | 92 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2014 | 168 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 236 | 0.020 |
Why?
|
| Community Health Services | 1 | 2015 | 207 | 0.020 |
Why?
|
| Smoking | 1 | 2020 | 1019 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2014 | 201 | 0.020 |
Why?
|
| Feathers | 1 | 2013 | 10 | 0.020 |
Why?
|
| Receptor, EphB2 | 1 | 2013 | 6 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2013 | 144 | 0.020 |
Why?
|
| Breeding | 1 | 2013 | 28 | 0.020 |
Why?
|
| Animals, Wild | 1 | 2013 | 24 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2016 | 844 | 0.020 |
Why?
|
| Liver | 1 | 2015 | 503 | 0.020 |
Why?
|
| Monocytes | 1 | 2014 | 275 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 637 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2021 | 2111 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2015 | 875 | 0.020 |
Why?
|
| Cell Count | 1 | 2011 | 140 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 704 | 0.020 |
Why?
|
| Health Behavior | 1 | 2015 | 568 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2015 | 1515 | 0.020 |
Why?
|
| Belgium | 1 | 2010 | 4 | 0.020 |
Why?
|
| DNA, Chloroplast | 1 | 2010 | 2 | 0.020 |
Why?
|
| DNA, Plant | 1 | 2010 | 10 | 0.020 |
Why?
|
| Netherlands | 1 | 2010 | 12 | 0.020 |
Why?
|
| Climate | 1 | 2010 | 20 | 0.020 |
Why?
|
| Germany | 1 | 2010 | 24 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2010 | 60 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 1004 | 0.020 |
Why?
|
| Europe | 1 | 2010 | 114 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 1559 | 0.020 |
Why?
|
| Geography | 1 | 2010 | 107 | 0.020 |
Why?
|
| Phylogeny | 1 | 2013 | 740 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 1845 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 2790 | 0.020 |
Why?
|
| Child | 1 | 2015 | 3381 | 0.020 |
Why?
|
| Computer Graphics | 1 | 2006 | 19 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 124 | 0.010 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 570 | 0.010 |
Why?
|
| Drosophila melanogaster | 1 | 2006 | 189 | 0.010 |
Why?
|
| Database Management Systems | 1 | 2003 | 19 | 0.010 |
Why?
|
| Peptide Library | 1 | 2003 | 27 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 2003 | 40 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2003 | 88 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2003 | 273 | 0.010 |
Why?
|